Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

(2016) D. C. Baumgart et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

(2016) Aurelien Amiot et al.   Clinical Gastroenterology and Hepatology

The safety of vedolizumab for ulcerative colitis and Crohn's disease

(2016) Jean-Frédéric Colombel et al.   GUT

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease

(2016) Amy L. Lightner et al.   Journal of Crohns & Colitis

Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

(2015) M. Rosario et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery

(2015) Cheryl Lau et al.   ANNALS OF SURGERY

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

The Comprehensive Complication Index

(2014) Ksenija Slankamenac et al.   ANNALS OF SURGERY

Operative Strategy Modifies Risk of Pouch-related Outcomes in Patients With Ulcerative Colitis on Preoperative Anti-Tumor Necrosis Factor-α Therapy

(2013) Jinyu Gu et al.   DISEASES OF THE COLON & RECTUM

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

New targets for mucosal healing and therapy in inflammatory bowel diseases

(2013) M F Neurath   Mucosal Immunology

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry

(2012) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Previous infliximab therapy and postoperative complications after proctocolectomy with ileum pouch anal anastomosis

(2012) Emma J. Eshuis et al.   Journal of Crohns & Colitis

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis

(2009) M. Ferrante et al.   INFLAMMATORY BOWEL DISEASES

Definition and grading of anastomotic leakage following anterior resection of the rectum: A proposal by the International Study Group of Rectal Cancer

(2009) Nuh N. Rahbari et al.   SURGERY